Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Cash Flow (2022 - 2025)

Axsome Therapeutics' Net Cash Flow history spans 4 years, with the latest figure at -$2.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 80.49% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached $7.6 million, up 110.7%, while the annual FY2025 figure was $7.6 million, 110.7% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$2.3 million at Axsome Therapeutics, down from $22.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $190.6 million in Q2 2023 and bottomed at -$54.8 million in Q1 2024.
  • The 4-year median for Net Cash Flow is -$6.8 million (2022), against an average of $14.8 million.
  • The largest annual shift saw Net Cash Flow soared 2687.71% in 2023 before it tumbled 219.88% in 2024.
  • A 4-year view of Net Cash Flow shows it stood at -$26.7 million in 2022, then dropped by 13.84% to -$30.4 million in 2023, then soared by 60.53% to -$12.0 million in 2024, then skyrocketed by 80.49% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Net Cash Flow are -$2.3 million (Q4 2025), $22.3 million (Q3 2025), and $2.1 million (Q2 2025).